Jonas Berg
Metabolic Health Writer
Jonas owns the GLP-1 and metabolic beat. He follows the incretin literature weekly and covers the widening gap between approved medications and research analogs.
New Study Compares Heart Outcomes for Tirzepatide and Semaglutide
A new paper in J Diabetes Metab Disord examines cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes.
FDA Approves Weekly Insulin for Type 2 Diabetes
The FDA has approved Onswik, a once weekly long acting insulin, for adults with type 2 diabetes.
VR Buffet Study Probes Ghrelin and Alcohol Cravings
A small trial used a virtual reality buffet to study ghrelin related pharmacology in people with alcohol use disorder.
Humanin Research Overview: What Studies Show About This Mitochondrial Peptide
A plain look at what published research actually shows about humanin, a peptide encoded inside mitochondrial DNA.
FDA Flags Safety Concerns With Unapproved GLP1 Weight Loss Drugs
FDA warns that compounded and unapproved GLP1 drugs, including retatrutide and cagrilintide, carry real safety and quality risks.
Semaglutide vs Tirzepatide: How They Compare
Semaglutide and tirzepatide are approved medications with different mechanisms and trial results, not research compounds.
GLP-1 Peptides for Weight Loss: The Complete Guide
A clear guide to GLP-1 peptides for weight loss: what the FDA has approved, and what compounds are still in clinical trials.